| Literature DB >> 17868864 |
Abstract
With the introduction of new diagnostic methods and treatment modalities, it has become increasingly clear that hypereosinophilic syndromes (HES) are a heterogeneous group of disorders for which a single approach to treatment is insufficient. This article discusses current treatment modalities for myeloproliferative HES, idiopathic HES, and lymphocytic-variant HES.Entities:
Mesh：
Year: 2007 PMID： 17868864 DOI： 10.1016/j.iac.2007.07.006
Source DB: PubMed Journal: Immunol Allergy Clin North Am ISSN： 0889-8561 Impact factor: 3.479